Subsequent to the development of resistance to first- or second-generation EGFR TKIs in EGFR mutant advanced NSCLC, patients benefit from osimertinib in the second-line setting if a EGFR T790M resistant mutation is identified [55]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.